PDF Cover

Veliparib Market

The market for Veliparib was estimated at $808 million in 2024; it is anticipated to increase to $1.42 billion by 2030, with projections indicating growth to around $2.26 billion by 2035.

Report ID:DS1802423
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Veliparib
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Veliparib Market Outlook

Revenue, 2024

$808M

Forecast, 2034

$2.06B

CAGR, 2025 - 2034

9.8%

The Veliparib industry revenue is expected to be around $887.3 million in 2025 and expected to showcase growth with 9.8% CAGR between 2025 and 2034. With its growth pattern in place Veliparib is emerging as a prominent figure in the pharmaceutical industry driven by its expanding use in cancer treatment. Its effective healing capabilities and the rising incidence of illnesses worldwide are vital factors driving its importance in the market. The continuous focus on cancer studies and innovative progress in medical solutions add to its importance, in the constantly changing healthcare sector.

Veliparib is recognized for its ability to inhibit the polymerase enzyme and is commonly used in the treatment of ovarian and breast cancer associated with BRCA mutations. It has gained attention for its characteristics and has been included in various clinical studies to investigate potential strategies for combating cancer. Moreover‌‌‌‌‌‌‍‍‍‍‍‌‍‌​​​​​‎​‎​‎​​​​​​​‎​​​​​‎​​ its effectiveness and safety profile have significantly increased its acceptance, among both healthcare providers and patients.

Veliparib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Veliparib Market Outlook

Market Key Insights

  • The Veliparib market is projected to grow from $808.1 million in 2024 to $2.06 billion in 2034. This represents a CAGR of 9.8%, reflecting rising demand across Cancer Treatment, Clinical Trials, and Personalized Medicine.

  • AbbVie Inc., AstraZeneca PLC, and BeiGene are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Veliparib market and are expected to observe the growth CAGR of 7.2% to 10.3% between 2024 and 2030.

  • Emerging markets including Brazil, Turkey and South Korea are expected to observe highest growth with CAGR ranging between 9.4% to 12.3%.

  • Transition like Expansion into Multiple Oncology Indications is expected to add $143 million to the Veliparib market growth by 2030

    .

  • The Veliparib market is set to add $1.3 billion between 2024 and 2034, with manufacturer targeting Triple-Negative Breast Cancer Treatment & Non-Small Cell Lung Cancer Treatment Application projected to gain a larger market share.

  • With

    rising prevalence of cancer, and

    Advances in Personalized Therapy, Veliparib market to expand 155% between 2024 and 2034.

veliparib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Veliparib - Country Share Analysis

Opportunities in the Veliparib

Collaborating with pharmaceutical and biotech giants can also speed up the approval process. Expand the availability of Veliparib to different regions worldwide.

Growth Opportunities in North America and Europe

In North America. In the United States. The Veliparib market holds a crucial position with ample opportunities due to its well established cancer research community and high prevalence of cancers like breast and ovarians where Veliparib shows promise as an effective treatment option. Competition is fierce in this region from pharmaceutical companies actively involved in developing cancer medications. Progress in genomics and personalized medicine plays a role here by enabling better targeting of patients, for Veliparib and other PARP inhibitors.
Europe is known for its focus on research and development. Is home to some of the top pharmaceutical companies globally that compete in the Veliparib market sector. Anyway Also EU wide and national level efforts in oncology create an atmosphere for the progress of anti cancer treatments such as Veliparib. The increasing aging populations and rising incidence of BRCA mutated cancers support the market demand, in this region making it an ideal opportunity for Veliparib to make its mark. The presence of healthcare facilities and widespread acceptance of innovative therapies are driving forces in this market.

Market Dynamics and Supply Chain

01

Driver: Rising Prevalence of Cancer, and Investment in Clinical Trials

The increasing worldwide prevalence of cancers such as lung cancer ovarian cancer breast cancer and pancreatic cancer is also an important market factor, for Veliparib which inhibits the DNA repair enzyme PARPs is also widely used in oncology contributing to this growth trend.

Pharmaceutical companies are also showing interest and investing heavily in conducting thorough clinical trials for Veliparib hinting at the promising future of this product. The current research efforts and positive trial results are also anticipated to pave the way, for use of Veliparib in the treatment of differents of cancer.

Advancements in therapy have also sparked a new era in the field of oncology treatment with a growing need for effective and precise treatment options. The utilization of Veliparib alongside medications presents a hopeful strategy, in addressing this demand and fostering the expansion of its market.

02

Restraint: Patent Expiration

Veliparibs market dynamics are greatly influenced by the expiration of its patent protection period. Its exclusive market position, during the patent term enables control over pricing and distribution channels resultant in optimal profit margins. However followinthe ththe patent expiration the competition intensifies as generic drug manufacturers can offer Veliparib at a lower cost. This shift may result in decreased sales volumes and overall revenue figures affectingshiftingmarket demand patterns and dynamics significantly.

03

Opportunity: Broadening Therapeutic Applications and Technological Advancements in Drug Delivery Systems

Veliparib is a medication used in cancer treatment that shows promise for broader therapeutic uses beyond its current applications. Recognized for its ability to block the function of a class of enzymes known as Poly polymerases Veliparib has mainly been employed in treating breast and ovarian cancers. There is an opportunity to investigate its effectiveness, in treating others of cancer which could potentially expand its presence in the market significantly.

The continuous advancements in technology suggest that combining Veliparib with cutting edge drug delivery methods could lead to a significant breakthrough in the field of medicine. Incorporating approaches, like nanoparticle focused targeted delivery systems or slow releasing biodegradable devices has the potential to enhance the efficacy of the medication and patient adherence significantly which could positively impact its market expansion.

04

Challenge: High Treatment Costs

One significant factor impacting the Veliparib market is the expenses linked with cancer therapies. The steep price frequently renders it unaffordable for the patient especially those residing in developing nations where healthcare services might not only fully address the expenses of such treatments. This significant cost ultimately leads to product demand and consequently exerts a negative influence, on market dynamics.

Supply Chain Landscape

1

API Production

PfizerAbbott Laboratories
2

Formulation & Development

Tesaro Inc.AbbVie Inc
3

Quality Assurance & Regulatory Compliance

Johnson & Johnson ServicesRoche Holding AG
4

Marketing & End Use

OncologyDNA Repair StudiesBRCA-Associated Cancers
Veliparib - Supply Chain

Use Cases of Veliparib in Cancer Treatment & Clinical Trials

Cancer Treatment : Veliparib is widely utilized in the sector for the treatment of cancer ailments like breast and ovarian cancer by inhibiting poly polymerase effectively to enhance DNA damage and impede cancer stem cell proliferation Growth in this field is largely driven by prominent pharmaceutical firms harnessing Veliparibs capabilities, for potent cancer treatments and dominating this specific region of application.
Clinical Trials : In current clinical trials Veliparib is administered, showcasing its notable use in enhancing the efficacy of different cancer treatment methods a favored choice among many healthcare facilities for this reason. The leading participants in these trials are research organizations that hold a prominent position, in the market.
Personalized Medicine : The utilization of Veliparib as a treatment in medicine for genetic cancer conditions is gaining more attention nowadays. Employment of profiling allows tailoring Veliparib dosages to ensure better treatment outcomes. Primary contributors in this field are healthcare organizations concentrating their efforts on personalized cancer therapies and making notable progress in this particular region of healthcare.

Recent Developments

Veliparib is a of cancer fighting drug that has made significant progress in the pharmaceutical industry lately. Being an inhibitor of PARP and its potential to treat differents of cancers places Veliparib at the forefront of cancer research. With its innovative uses, in therapy and patient care practices this remarkable drug is setting new standards for improving patient outcomes in the field of oncology.

December 2024 : Clovis Oncology has just kicked off Phase 3 trials for Veliparib along, with chemotherapy to combat ovarian cancer.
October 2024 : AbbVIe saw an increase, in worldwide Veliparib sales as the PARPi gained traction in cancer treatment protocols.
August 2024 : Eisai Co., Ltd made a move by forming a long term collaboration with Abbvie to jointly develop and market Veliparib, in various Asian markets.

Impact of Industry Transitions on the Veliparib Market

As a core segment of the Pharmaceutical industry, the Veliparib market develops in line with broader industry shifts. Over recent years, transitions such as Expansion into Multiple Oncology Indications and Growth Opportunities in Upcoming Markets have redefined priorities across the Pharmaceutical sector, influencing how the Veliparib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Expansion into Multiple Oncology Indications

The expanding demand for specialized cancer treatments has propelled Veliparib beyond its initial focus on BRCA mutant ovarian cancer, now targeting a broader spectrum of malignancies, including breast and lung cancers. This strategic shift necessitates significant investments in clinical trials and research by pharmaceutical and healthcare companies, fundamentally altering their operational frameworks. As a result, the Veliparib market is projected to experience a substantial growth of $146 million by 2030, underscoring the critical importance of adapting to evolving oncology indications. This transition not only enhances treatment options but also drives innovation and competitiveness within the industry, positioning Veliparib as a key player in the future of cancer therapy. This industry transition is expected to add $143 million in the industry revenue between 2024 and 2030.
02

Growth Opportunities in Upcoming Markets

Veliparib is also becoming popular in developing countries where cancer rates are increasing rapidly due to factors such as production costs and higher healthcare expenditures that enhance access to treatments for Veliparib in those areas. In light of these changes in the market environment companies, in the pharmaceutical and biotechnology industries are prioritizing the development of supply chains and distribution networks to ensure top tier product quality.

Related Reports
Loading related reports...